NextPoint Therapeutics, Inc. is a clinical-stage biotechnology firm that is developing precision oncology therapeutics. NextPoint Therapeutics' commitment to pioneering new avenues in cancer treatment, aiming to create therapies that are more effective and less invasive, potentially offering new alternatives to patients with various types of cancer. Their approach is grounded in precision medicine, seeking to tailor treatments that can directly target cancer cells while minimizing harm to healthy tissues
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/14/2024 | Series B | $122.48MM | $xx.xx | $268.64MM | Arkin Bio-Capital, Bayer, Binney Street Capital, Catalio Capital, Gordon Freeman, Invus, Mpm Capital, Pagodatree Partners, Sanofi Ventures, Sixty Degree Capital, Wtt Investment | |
Price per Share
$xx.xx
Shares Outstanding
20,413,230
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arkin Bio-Capital, Bayer, Binney Street Capital, Catalio Capital, Gordon Freeman, Invus, Mpm Capital, Pagodatree Partners, Sanofi Ventures, Sixty Degree Capital, Wtt Investment
|
||||||
08/31/2020 | Series A | $15.53MM | $xx.xx | $127.44MM | Binney Street Capital, Gordon Freeman, Mpm Capital | |
Price per Share
$xx.xx
Shares Outstanding
4,436,175
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Binney Street Capital, Gordon Freeman, Mpm Capital
|
||||||
08/31/2020 | Series A-2 | $22.7MM | $xx.xx | $127.44MM | Binney Street Capital, Gordon Freeman, Mpm Capital | |
Price per Share
$xx.xx
Shares Outstanding
3,783,440
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Binney Street Capital, Gordon Freeman, Mpm Capital
|
||||||
12/31/2018 | Series Seed | $2.4MM | $xx.xx | $8MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,400,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|